Insider · CIK 0002112941
John Woodson Rollins
Files at AIDX (20/20 Biolabs, Inc.). First filing -, latest -.
In brief
John Woodson Rollins files SEC Form 4 as director at AIDX (20/20 Biolabs, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; John Woodson Rollins has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 4 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 19, 2026 | AIDX 20/20 Biolabs, Inc. | CConversion Common Stock | +13,029 | $0.00 | $0 | 24,140 | Feb 23, 2026 |
| Feb 19, 2026 | AIDX 20/20 Biolabs, Inc. | CConversion Common Stock | +6,135 | $0.00 | $0 | 30,275 | Feb 23, 2026 |
| Feb 19, 2026 | AIDX 20/20 Biolabs, Inc. | CConversion Series A Preferred Stockderivative | -13,029 | - | - | 0 | Feb 23, 2026 |
| Feb 19, 2026 | AIDX 20/20 Biolabs, Inc. | CConversion Series A-2 Preferred Stockderivative | -6,135 | - | - | 0 | Feb 23, 2026 |
Questions about John Woodson Rollins
Answered from the filings on this page, as of the latest one.
Is John Woodson Rollins buying or selling?
John Woodson Rollins has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did John Woodson Rollins's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and John Woodson Rollins has 0.
Where does John Woodson Rollins file Form 4?
John Woodson Rollins has filed Form 4 at AIDX (20/20 Biolabs, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.